Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.

Results from the phase 3 HERO trial(NCT03085095), presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program, indicated that relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone suppression through 48 weeks, fast testosterone recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate […]

Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer Radiotherapy: validation of voxel-based models in an independent population.

/Objectives: Recent voxel-based studies have shown that the dose to specific rectal and urethro-vesical subregions is predictive of toxicities, following prostate cancer IMRT. The objective of this study was to validate the discriminatory power of these subregions with respect to the whole organs, in a large independent population.

The DNA methylation landscape of advanced prostate cancer.

Although DNA methylation is a key regulator of gene expression, the comprehensive methylation landscape of metastatic cancer has never been defined. Through whole-genome bisulfite sequencing paired with deep whole-genome and transcriptome sequencing of 100 castration-resistant prostate metastases, we discovered alterations affecting driver genes that were detectable only with integrated whole-genome approaches.

X